Pharma BD Deal Intelligence
Sepracor's Latuda became a true blockbuster that carried Dainippon Sumitomo for over a decade, but the 2023 patent cliff triggered a company-wide financial crisis, mass layoffs, and goodwill/patent impairments — leaving the deal's long-run verdict as a high-amplitude boom-bust rather than durable value creation.
Full analysis, sources & comparables →Deutsche Bank's David Steinberg said the deal would lift Dainippon to the #6 Japanese drugmaker; BMO Capital's Robert Hazlett said Sepracor's…
C&EN framed the takeover as Dainippon Sumitomo's entry vehicle into the US specialty market, leveraging Sepracor's Lunesta/Xopenex commercial muscle to launch…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$23/share = ~$2.6B cash tender. CNS/respiratory specialty pharma (Lunesta, Xopenex). Closed Oct 20, 2009. Source: Sumitomo Pharma news, WilmerHale, Bloomberg.
Sepracor's Latuda became a true blockbuster that carried Dainippon Sumitomo for over a decade, but the 2023 patent cliff triggered a company-wide financial crisis, mass layoffs, and goodwill/patent impairments — leaving the deal's long-run verdict as a high-amplitude boom-bust rather than durable value creation.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Dainippon Sumitomo Pharma Co., Ltd. / Sepracor Inc. (this deal) | 2009 | $2.6B | 63 |
| Dainippon Sumitomo Pharma Co., Ltd. / Boston Biomedical, Inc. | 2012 | $2.6B | 24 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| QIAGEN N.V. / DxS Ltd. | 2009 | $130M | 85 |
← Browse all deals · How we score deals
More: 2009 deals